ALFACALCIDOL IN TREATMENT OF OSTEOPOROSIS
- Autores: Baranova I.A1
-
Afiliações:
- FSBEI he RNSMU n.a. N.I. Pirogov of RMH
- Edição: Nº 5 (2017)
- Páginas: 82-85
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289812
- ID: 289812
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The increase in the life expectancy of people has led to an increase in the prevalence of some «age-related» diseases, including osteoporosis (OP), a systemic disease of the skeleton, accompanied by brittleness of bones. The development of OP is closely related to vitamin D deficiency. On the basis of natural vitamins D2 and D3, their active metabolites and synthetic analogues, a significant amount of vitamin products and drugs has been created in various dosage forms that are widely used to prevention and treatment not only OP but also other diseases. This article considers the potentials for the clinical use of the active metabolite alfacalcidol, a prodrug, which is activated in the liver and bone tissue with formation of D-hormone after intake. Alfacalcidol is more effective than native vitamin D, it increases the bone mineral density and its strength, regardless of calcium absorption and inhibition of parathyroid hormone activity. It is shown that this drug reduces the incidence of falls in elderly patients. Alfacalcidol has therapeutic and prophylactic effects in various forms of OP and can be used both as monotherapy and in combination with other anti-osteoporotic drugs.
Palavras-chave
Texto integral
Sobre autores
I. Baranova
FSBEI he RNSMU n.a. N.I. Pirogov of RMH
Email: iribaranova@yandex.ru
MD, Prof. Moscow
Bibliografia
- Рекомендации Российской ассоциации по остеопорозу «Профилактика, диагностика и лєчєние дефицита витамина D и кальций среди взрослого населения и у пациентов с остеопорозом» / Под ред. Ü.M. Лєсняк. М., 2016. 96 с.
- Шварц Г.Я. Фармакотерапия остеопороза. М., 2002. 368 с.
- Schacht E., Richy F., Reginster J.Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J. Musculoskelet. Neuronal Interact. 2005;5(3):273-84.
- Sato Y., Maruoka H., Oizumi K. Amelioration of hemiplegiaassociated osteopenia more than 4 years after stroke by 1·-hydroxyvitamin D3 and calcium supplementation. Stroke. 1997;28:736-39.
- Sato Y., Manabe S., Kuno H., Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1·-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 1999;66:64-8.
- Hayashi Y., Fujita T., Inoue T. Decrease of vertebral fracture in osteoporotics by administration of lalphahydroxyvitamin D3. JBMR. 1992;10(50):184-88.
- Orimo H., Shiraki M., Hayashi Y., Hoshino T., Onaya T., Miyazaki S., Kurosawa H., Nakamura T., Ogawa N. Effects of 1-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 1994;54:370-76.
- Tanizawa T., Imura K., Ishii Y., Nishida S., Takano Y., Mashiba T., Endo N., Takahashi H.E. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporos. Int. 1999;9:163-70.
- Papadimitropoulos E., Wells G., Shea B., Gillespie W., Weaver B., Zytaruk N., Cranney A., Adachi J., Tugwell P., Josse R., Greenwood C., Guyatt G. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VIP: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr. Rev. 2002;23(4):560-69.
- Richy F., Ethgen O., Bruyere O., Reginster J.Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos. Int. 2004;15(4):301-10.
- Richy F., Schacht E., Bruyere O., Ethgen O., Gourlay M., Reginster J.Y. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif. Tissue Int. 2005;76(3):176-86.
- Ones K., Schacht E., Dukas L. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in poatmenopausal osteoporosis: a two-years randomized multiarm controlled trial. Inrernet J. Endocrinol. 2007;4, published online.
- Ebina K., Kashii M., Hirao M., Hashimoto J., Noguchi T., Koizumi K., Kitaguchi K., Matsuoka H., Iwahashi T., Tsukamoto Y., Yoshikawa H. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis. J. Bone Miner. Metab. 2016 Nov 9. [Epub ahead of print].
- Sorensen O.H., Lind B., Saltin B., Lund B., Andersen R.B., Hjorth L., Meisen F., Mosekilde L. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin. Sci. (Lond). 1979;56(2):157-6T
- Verhaar H.J., Samson M.M., Jansen P.A., de Vreede P.L., Manten J.W., Duursma S.A. Muscle strength, functional mobility and vitamin D in older women. Aging (Milano). 2000;12:455-60.
- Dukas L., Bischoff H.A., Lindpaintner L.S., Schacht E., Birkner-Binder D., Damm T.N., Thalmann В., Stähelin Н.В. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J. Am. Geriatr. Soc. 2004;52:230-36.
- Richy F., Dukas L., Schacht E. Differential effects of D-Hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif. Tissue Int. 2008;82(2):102-7.
- de Nijs R.N., Jacobs J.W., Algra A., Lems W.F., Bijlsma J.W. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with metaanalysis of randomized controlled trials including organ transplantation studies. Osteoporos. Int. 2004;15(8):589-602.
- Lekamwasam S., Adachi J.D., Agnusdei D., Bilezikian J., Boonen S., Borgström F., Cooper C., Diez Perez A., Eastell R., Hofbauer L.C., Kanis J.A., Langdahl B.L., Lesnyak O., Lorenc R., McCloskey E., Messina O.D., Napoli N., Obermayer-Pietsch В., Ralston S.H., Sambrook P.N., Silverman S., Sosa M., Stepan J., Suppan G., Wahl D.A., Compston J.E.; Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos. Int. 2012;23(9): 2257-76.
- Лесняк О.М., Баранова И.А., Торопцова Н.В. Клинические рекомендации «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». Ярославль, 2013. 48 с.
Arquivos suplementares
